BR112012011485A2 - "composições e métodos para tratar náusea e vômito centralmente mediados". - Google Patents

"composições e métodos para tratar náusea e vômito centralmente mediados".

Info

Publication number
BR112012011485A2
BR112012011485A2 BR112012011485A BR112012011485A BR112012011485A2 BR 112012011485 A2 BR112012011485 A2 BR 112012011485A2 BR 112012011485 A BR112012011485 A BR 112012011485A BR 112012011485 A BR112012011485 A BR 112012011485A BR 112012011485 A2 BR112012011485 A2 BR 112012011485A2
Authority
BR
Brazil
Prior art keywords
vomiting
methods
compositions
centrally mediated
treating
Prior art date
Application number
BR112012011485A
Other languages
English (en)
Other versions
BR112012011485B1 (pt
Inventor
Cantoreggi Sergio
Bonadeo Daniele
Trento Fabio
Rossi Giorgia
Braglia Riccardo
Cannella Roberta
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43608757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012011485(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of BR112012011485A2 publication Critical patent/BR112012011485A2/pt
Publication of BR112012011485B1 publication Critical patent/BR112012011485B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Paints Or Removers (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"composição e métodos para tratar náusea e vômito centralmente mediados". são fornecidos composições e métodos para tratr ou prevenir náusea e vômito em pacientes que são submetidos à quimioterapia, radiotepia ou cirurgia.
BR112012011485-9A 2009-11-18 2010-11-18 Forma de dosagem e cápsula para tratar náusea e vômito BR112012011485B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26247009P 2009-11-18 2009-11-18
US61/262,470 2009-11-18
US38270910P 2010-09-14 2010-09-14
US61/382,709 2010-09-14
PCT/IB2010/003106 WO2011061622A1 (en) 2009-11-18 2010-11-18 Compositions for treating centrally mediated nausea and vomiting

Publications (2)

Publication Number Publication Date
BR112012011485A2 true BR112012011485A2 (pt) 2018-04-03
BR112012011485B1 BR112012011485B1 (pt) 2021-06-29

Family

ID=43608757

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012011485-9A BR112012011485B1 (pt) 2009-11-18 2010-11-18 Forma de dosagem e cápsula para tratar náusea e vômito

Country Status (39)

Country Link
US (1) US20230263799A1 (pt)
EP (3) EP2361090B1 (pt)
JP (1) JP5890780B2 (pt)
KR (1) KR101615108B1 (pt)
CN (6) CN106421793B (pt)
AP (1) AP3083A (pt)
AU (1) AU2010320598B2 (pt)
BR (1) BR112012011485B1 (pt)
CA (1) CA2778301C (pt)
CL (1) CL2012001276A1 (pt)
CO (1) CO6551693A2 (pt)
CR (1) CR20120216A (pt)
CU (1) CU24048B1 (pt)
CY (1) CY1118062T1 (pt)
DK (2) DK2722045T3 (pt)
DO (1) DOP2012000138A (pt)
EA (1) EA026815B1 (pt)
EC (1) ECSP12011907A (pt)
ES (4) ES2559475T3 (pt)
GE (1) GEP20156226B (pt)
GT (1) GT201200156A (pt)
HK (2) HK1214148A1 (pt)
HR (3) HRP20140759T1 (pt)
HU (1) HUE029677T2 (pt)
IL (1) IL219576A (pt)
LT (1) LT2722045T (pt)
MA (1) MA33810B1 (pt)
MX (1) MX2012005347A (pt)
MY (1) MY159393A (pt)
NI (1) NI201200090A (pt)
NZ (1) NZ599439A (pt)
PE (1) PE20121483A1 (pt)
PL (3) PL2722045T3 (pt)
PT (2) PT2361090E (pt)
RS (2) RS53491B1 (pt)
SI (2) SI2361090T1 (pt)
SM (1) SMT201400112B (pt)
TN (1) TN2012000170A1 (pt)
WO (1) WO2011061622A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
EP2361090B1 (en) 2009-11-18 2014-05-21 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
EP2729147B1 (en) 2011-07-04 2017-09-06 IRBM - Science Park S.p.A. Nk-1 receptor antagonists for treating corneal neovascularisation
CN106974912A (zh) 2011-10-18 2017-07-25 赫尔辛医疗股份公司 奈妥匹坦和帕洛诺司琼的治疗性组合
US9403772B2 (en) 2011-11-29 2016-08-02 Helsinn Healthcare Sa 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
CN103520725B (zh) * 2012-07-05 2017-10-24 海思科医药集团股份有限公司 一种治疗呕吐的药物组合物
CN106902086B (zh) * 2015-12-23 2020-10-20 江苏恒瑞医药股份有限公司 一种包含奈妥匹坦的固体组合物
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
CN108721214B (zh) * 2017-04-14 2020-06-16 和龙 奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途
CN108853010A (zh) * 2017-05-15 2018-11-23 和龙 奈妥吡坦环糊精包合物、复方组合制剂及其制备方法和用途
CN109200018A (zh) * 2017-07-04 2019-01-15 南京诺瑞特医药科技有限公司 含有奈妥吡坦的微乳制剂
CN111343981A (zh) * 2017-11-17 2020-06-26 万达制药公司 使用川地匹坦治疗胃肠疾病的方法
MX2020008137A (es) * 2018-02-02 2020-10-19 Eustralis Pharmaceuticals Ltd Trading As Pressura Neuro Formulaciones orales y usos de las mismas.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970007917B1 (ko) 1989-11-28 1997-05-17 신텍스 인크. 신규 삼환식 화합물
US5510486A (en) 1994-07-26 1996-04-23 Syntex (U.S.A.) Inc. Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
ATE277905T1 (de) 1999-02-24 2004-10-15 Hoffmann La Roche 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
CZ303639B6 (cs) 2000-07-14 2013-01-23 F. Hoffmann-La Roche Ag N-Oxid derivátu 4-fenylpyridinu, zpusob jeho prípravy a lécivo s jeho obsahem
ES2272408T3 (es) 2000-12-14 2007-05-01 F. Hoffmann-La Roche Ag Matriz lipidica autoemulsificante (selm).
JP5690461B2 (ja) 2002-11-15 2015-03-25 ヘルシン ヘルスケア ソシエテ アノニム 化学療法誘導嘔吐を治療するためのパロノセトロン
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
TWI355936B (en) 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
WO2004091622A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CA2642922C (en) * 2006-02-23 2011-08-02 Pfizer Limited Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
TWI367212B (en) * 2006-10-24 2012-07-01 Helsinn Healthcare Sa Dosage forms of palonosetron hydrochloride having improved stability and bioavailability
US20110014117A1 (en) * 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
MX2010006854A (es) * 2007-12-18 2010-09-09 Schering Corp Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina.
EP2361090B1 (en) 2009-11-18 2014-05-21 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting

Also Published As

Publication number Publication date
KR20120101456A (ko) 2012-09-13
NZ599439A (en) 2014-06-27
SI2361090T1 (sl) 2014-09-30
CN104856999A (zh) 2015-08-26
ES2595077T3 (es) 2016-12-27
EP2722044B1 (en) 2017-01-04
TN2012000170A1 (en) 2013-12-12
CN106421793A (zh) 2017-02-22
MX2012005347A (es) 2012-08-03
DOP2012000138A (es) 2012-11-15
WO2011061622A1 (en) 2011-05-26
HRP20161277T1 (hr) 2016-11-18
KR101615108B1 (ko) 2016-05-12
CN106421793B (zh) 2023-06-16
MA33810B1 (fr) 2012-12-03
IL219576A0 (en) 2012-06-28
ES2559475T3 (es) 2016-02-12
JP2013511507A (ja) 2013-04-04
AP2012006278A0 (en) 2012-06-30
SMT201400112B (it) 2014-11-10
CN107050455B (zh) 2020-09-29
CY1118062T1 (el) 2017-06-28
PL2722044T3 (pl) 2017-08-31
GT201200156A (es) 2014-03-27
HUE029677T2 (hu) 2017-03-28
EA026815B1 (ru) 2017-05-31
DK2361090T3 (da) 2014-08-25
PT2722045T (pt) 2016-10-18
PT2361090E (pt) 2014-09-03
JP5890780B2 (ja) 2016-03-22
PL2722045T3 (pl) 2017-03-31
CA2778301C (en) 2016-06-14
HK1214147A1 (zh) 2016-07-22
MY159393A (en) 2016-12-30
PL2361090T3 (pl) 2014-10-31
CN102655864A (zh) 2012-09-05
CN106512010A (zh) 2017-03-22
CR20120216A (es) 2012-07-24
AU2010320598A1 (en) 2012-06-14
US20230263799A1 (en) 2023-08-24
ES2623503T3 (es) 2017-07-11
NI201200090A (es) 2012-11-13
BR112012011485B1 (pt) 2021-06-29
EP2727590B1 (en) 2015-10-21
CA2778301A1 (en) 2011-05-26
RS53491B1 (en) 2015-02-27
ECSP12011907A (es) 2012-10-30
CL2012001276A1 (es) 2012-12-07
CU24048B1 (es) 2014-12-26
HRP20170419T1 (hr) 2017-06-02
EP2727590A1 (en) 2014-05-07
CO6551693A2 (es) 2012-10-31
HK1214148A1 (zh) 2016-07-22
CN107050455A (zh) 2017-08-18
HRP20140759T1 (hr) 2014-10-24
EP2361090A1 (en) 2011-08-31
EP2722044A1 (en) 2014-04-23
AU2010320598B2 (en) 2016-06-16
PE20121483A1 (es) 2012-12-02
DK2722045T3 (en) 2016-10-24
RS55206B1 (sr) 2017-01-31
SI2722045T1 (sl) 2017-02-28
EA201290356A1 (ru) 2012-12-28
LT2722045T (lt) 2016-09-26
AP3083A (en) 2015-01-31
CU20120078A7 (es) 2012-10-15
CN104856998A (zh) 2015-08-26
EP2361090B1 (en) 2014-05-21
ES2494015T3 (es) 2014-09-12
IL219576A (en) 2017-08-31
GEP20156226B (en) 2015-01-26

Similar Documents

Publication Publication Date Title
BR112012011485A2 (pt) "composições e métodos para tratar náusea e vômito centralmente mediados".
ECSP099634A (es) Derivados de piridazinona útiles como inhibidores de glucano sintasa
BRPI0511396A (pt) derivados de retinal e métodos para uso no tratamento de enfermidades visuais
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
NO20083202L (no) ANG2- og VEFG-inhibitorkombinasjoner
CR20120202A (es) Métodos y composiciones para tratar cáncer
BR112015007878A2 (pt) composto compreendendo oligonucleotídeo modificado, composição, combinação e uso dos mesmos
ATE531721T1 (de) Cyanoaminochinolone als gsk-3-inhibitoren
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
MX2009012690A (es) Composiciones, metodos, dispositivos y sistemas para el cuidado bucal.
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
MY160041A (en) Compositions and methods for treating parasitic infections
NO20082120L (no) Behandling og forebyggelse av mikroangiopati
HK1137028A1 (en) Phosphadiazine hcv polymerase inhibitors iv
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
EA201070059A1 (ru) Композиции, содержащие ингибиторы триптофангидроксилазы
BR112014014319A2 (pt) composições de cuidado oral
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis
BRPI0816952A2 (pt) Composição para tratar ou contralar uma infecção em um indivíduo, e, usos de uma fluoroquinolona e de uma combinação
MX2009003022A (es) Composiciones y metodos para tratar picaduras de medusa.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/11/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, , QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.